Anti-CD25 for tumour specific cell depletion
AssigneesTusk Therapeutics Ltd., Cancer Research Technology Limited
InventorsAnne Goubier, Beatriz Goyenechea Corzo, Josephine Salimu, Kevin Moulder, Pascal Merchiers, Mark Brown, James Geoghegan, Bianka Prinz, Sergio Quezada
Life of this patent
Estimating the term…
Abstract
The present disclosure provides antibody sequences found in antibodies that bind to human CD25, in particular an anti CD25-a-674 antibody which do not block the binding of CD25 to IL-2 or IL-2 signalling. The claimed antibody binds to the epitopes: QCVQGYRA and RWTQPQLICTG on CD25 Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical compositions and methods of treatment, in particular for treating cancer.
Claims26
An antibody or antigen-binding fragment thereof comprising a variable heavy chain comprising SEQ ID NO:
- 5 (aCD25-a-674-HCDR123) and a variable light chain comprising SEQ ID NO:
- 9 (aCD25-a-674-LCDR123).
Dependencies are inferred from the claim text.